DIAGNOS Announces $2.0 Million Brokered Private Placement Led by Centurion One Capital

Executive Summary

• Diagnos Inc. announced a brokered private placement to raise up to C$2,000,000 by selling up to 6,666,667 units at $0.30 per unit on a best‑efforts basis.
• Each unit consists of one common share and one common share purchase warrant (exercisable at $0.40 for 18 months). The company may increase the offering by an additional 2,500,000 units for up to $750,000.
• Proceeds will be used for regulatory affairs, product development, business development, and general corporate purposes; closing is expected around December 3, 2025 with a four‑month hold period.

Key Details

• Lead Agent / Bookrunner: Centurion One Capital Corp. (sole bookrunner).
• Units Offered: Up to 6,666,667 units at an issue price of $0.30 per unit.
• Unit Composition: 1 common share + 1 common share purchase warrant.
• Warrant Terms: Exercise price $0.40 per share; exercisable any time during the 18‑month period following the closing date.
• Option to Increase Offering: Agent granted option (exercisable up to 2 business days before final closing) to issue an additional 2,500,000 units for up to $750,000 gross proceeds.
• Gross Proceeds Target: Approximately C$2,000,000 (plus potential extra $750,000).
• Use of Proceeds: Regulatory affairs, product development, business development, and general corporate purposes.
• Closing Date: Expected on or around December 3, 2025 (subject to approvals, including TSX Venture Exchange).
• Hold Period: Four months and one day from the closing date under Canadian securities law.
• Geographic Offering Scope: Private placement in British Columbia, Alberta, Ontario, Quebec, the United States (exempt offering), and other jurisdictions as mutually agreed.
• Related Party Participation: Up to ~50% of the units may be purchased by related parties; expected to be exempt from formal valuation and minority‑shareholder approval under MI 61‑101 because neither fair market value nor consideration is anticipated to exceed 25% of market capitalization.

Notable Quotes

(No executive quotes were provided in the release.)